{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:23:43Z","timestamp":1771935823999,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aims to evaluate the potential of CT-based habitat radiomics in predicting BRCA mutation status in patients with high-grade serous ovarian cancer (HGSOC). The goal is to identify radiomic features from distinct tumor habitats that correlate with BRCA mutations and assess the predictive accuracy of various machine learning models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 228 patients with histologically confirmed HGSOC were included in this multicenter, retrospective study, with 168 patients in the training cohort and 60 patients in the test cohort. Radiomic features were extracted from the entire tumor and subdivided into five distinct \u201chabitats\u201d based on local tumor features. Predictive models were developed for each of the following: clinical model, radiomics model (based on whole tumor characteristics), five habitat models (habitat1, habitat2, habitat3, habitat4, habitat5), and a combined habitat model (integrating habitat1\u20135). Five machine learning algorithms (logistic regression (LR), support vector machine (SVM), light gradient boosting machine (LightGBM), extreme gradient boosting (XGBoost)) were applied to each model. The model with the highest average area under the curve (AUC) across the algorithms in the training cohort was selected as the optimal model. Further comparison and evaluation of the optimal models from different algorithms were performed to determine the most reliable one.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the five machine learning algorithms, XGBoost showed the highest AUC in the training cohort but exhibited a significant drop in the test cohort, indicating overfitting. In contrast, the SVM model demonstrated more consistent performance across both cohorts, with an AUC of 0.952 in the training cohort and 0.841 in the test cohort, making it the most stable performer among the tested algorithms for predicting BRCA mutation status. Calibration and net benefit analyses further confirmed the potential of the SVM-based habitat model as a non-invasive exploratory tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CT-based habitat radiomics offers a promising, non-invasive method for predicting BRCA mutation status in HGSOC. The combined habitat model outperformed traditional clinical and whole-tumor radiomic models by more effectively capturing tumor heterogeneity. SVM, demonstrating stable and reliable performance across datasets, emerged as the most robust model for clinical use. These findings support the integration of habitat radiomics, particularly SVM, for personalized, non-invasive molecular assessment in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1784439","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:34:09Z","timestamp":1771392849000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Habitat radiomics based on CT for assessing BRCA mutation status in patients with high-grade serous ovarian cancer: a multicenter study"],"prefix":"10.3389","volume":"16","author":[{"given":"Shuai","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Radiology, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huayuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Qingzhou People\u2019s Hospital","place":["Weifang, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Qingzhou People\u2019s Hospital","place":["Weifang, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Qingzhou People\u2019s Hospital","place":["Weifang, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengjian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinwen","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinping","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial ovarian cancer: Evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e174013","DOI":"10.1172\/JCI174013","article-title":"Biology-driven therapy advances in high-grade serous ovarian cancer","volume":"134","author":"Wang","year":"2024","journal-title":"J Clin Invest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw142","article-title":"BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer","volume":"27","author":"Moschetta","year":"2016","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz104","article-title":"Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option","volume":"30","author":"Buechel","year":"2019","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.5018","article-title":"New therapies for ovarian cancer","volume":"17","author":"O\u2019Malley","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.08.028","article-title":"High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation","volume":"369","author":"Gorodnova","year":"2015","journal-title":"Cancer Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.05.036","article-title":"BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study","volume":"217","author":"Petrillo","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000543869","article-title":"Impact on global health status, quality-sexual life and chronic fatigue state of risk-reducing salpingo-oophorectomy in women who are BRCA1\/2 mutation carriers: experience from a third-level italian center","volume":"90","author":"Della Corte","year":"2025","journal-title":"Gynecol Obstet Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.15.15199","article-title":"Ovarian cancer, the revised FIGO staging system, and the role of imaging","volume":"206","author":"Javadi","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2017161697","article-title":"High-grade serous ovarian cancer: associations between BRCA mutation status, CT imaging phenotypes, and clinical outcomes","volume":"285","author":"Nougaret","year":"2017","journal-title":"Radiology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1477759","article-title":"CT-based radiomics predicts HRD score and HRD status in patients with ovarian cancer","volume":"14","author":"Wu","year":"2025","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/02841851231188915","article-title":"CT-based radiomics nomogram analysis for assessing BRCA mutation status in patients with high-grade serous ovarian cancer","volume":"64","author":"Cao","year":"2023","journal-title":"Acta Radiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-018-1840-5","article-title":"Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer","volume":"44","author":"Meier","year":"2019","journal-title":"Abdom Radiol (NY)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1252074","article-title":"Habitat-based radiomics enhances the ability to predict lymphovascular space invasion in cervical cancer: a multi-center study","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00563","article-title":"Multi-habitat based radiomics for the prediction of treatment response to concurrent chemotherapy and radiation therapy in locally advanced cervical cancer","volume":"10","author":"Fang","year":"2020","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-024-00692-w","article-title":"Habitat-based radiomics analysis for evaluating immediate response in colorectal cancer lung metastases treated by radiofrequency ablation","volume":"24","author":"Huang","year":"2024","journal-title":"Cancer Imaging"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1559398","article-title":"Habitat-based radiomics for preoperative differentiation between early-stage serous borderline ovarian tumors and Malignant ovarian tumors","volume":"15","author":"Yu","year":"2025","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12880-025-01865-0","article-title":"CT-based radiomics model for noninvasive prediction of progression-free survival in high-grade serous ovarian carcinoma: a multicenter study incorporating preoperative and postoperative clinical factors","volume":"25","author":"Yu","year":"2025","journal-title":"BMC Med Imaging"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2399759","article-title":"Predicting BRCA mutation and stratifying targeted therapy response using multimodal learning: a multicenter study","volume":"56","author":"Li","year":"2024","journal-title":"Ann Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S284220","article-title":"MDCT-based radiomics features for the differentiation of serous borderline ovarian tumors and serous Malignant ovarian tumors","volume":"13","author":"Yu","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2214\/AJR.15.15451","article-title":"CT textural analysis of large primary renal cell carcinomas: pretreatment tumor heterogeneity correlates with histologic findings and clinical outcomes","volume":"207","author":"Lubner","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.14141477","article-title":"Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study","volume":"274","author":"Vargas","year":"2015","journal-title":"Radiology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.948767","article-title":"Habitat radiomics analysis of pet\/ct imaging in high-grade serous ovarian cancer: Application to Ki-67 status and progression-free survival","volume":"13","author":"Wang","year":"2022","journal-title":"Front Physiol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1784439\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:31:10Z","timestamp":1771932670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1784439\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1784439"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1784439","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"article-number":"1784439"}}